Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors

Trial Profile

Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Palbociclib (Primary) ; PD 325901 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2017 Results assessing thymidine kinase activity as a predictor of CDK4/6 inhibition, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 29 Jan 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 13 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top